30,980 Alzheimer's and dementia studies in plain English, each scored out of 100.
One hundred ninety-eight of 229 participants had WMH volumes available at both time-points. 5 key findings →
Design: longitudinal study Participants: 229 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among 11 601 participants (mean [SD] age, 59.18 [9.41] years; 5569 male [48.0%]), 9145 (78.8%) were exposed to at least 1 ACE indicator, 4241 (36.6%) to at least 1 AAE indicator, and 3531 (30.4%) to both ACE and AAE markers. 5 key findings →
Design: cohort study Participants: 601 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among eligible participants (n = 705,061), 264,294 individuals (37.5% of eligible participants) initiated any statin during 2001-2010 ("initiators"), of whom 249,613 (94.4%) were matched with 255,937 unique noninitiators to create the analytic sample (322,358 unique participants; mean age at baseline = 67.4 years; 55.1% female). 3 key findings →
Design: cohort Participants: 322,358 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
These findings indicate that AWV recipients had a timelier first MCI diagnosis than those who did not receive an AWV, but first ADRD diagnosis differed little. 5 key findings →
Design: cohort Participants: 549,516 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Our findings suggest that statins might be associated with a lower risk of incident AD among individuals with the APOE ε4 allele. 5 key findings →
Design: cohort Participants: 4,807 Evidence: early
Full summary, score breakdown and related studies → Original source Free full text
In this cohort study, high adherence to a flavonoid-rich diet score was associated with a lower risk of dementia, with reductions more pronounced in individuals with a high genetic risk, hypertension, and depressive symptoms. 5 key findings →
Design: cohort Participants: 121,986 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
After a median follow-up of 6.3 years, 678 individuals were diagnosed with dementia. 4 key findings →
Design: cohort Participants: 84,854 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A substantial proportion of the relationship between education and dementia was mediated through mid-life vascular risk factors. 2 key findings →
Design: cohort Participants: 13,368 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
New PRSs for dementia significantly improve risk-prediction performance, but still account for less risk than APOE genotype overall. 3 key findings →
Design: cohort Participants: 12,031 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Experimental evidence suggests that activated microglia induce astrocyte reactivity in neurodegenerative disorders, such as Alzheimer's disease (AD). 3 key findings →
Design: cohort Participants: 352 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Biomarkers were measured in 431 Black and 583 White participants (mean age of 77 and 80 years and 17% and 21% of men, respectively), generating a balanced sample of 366:366. 3 key findings →
Design: cohort Participants: 1,014 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Higher concentrations of serum biomarkers were associated with the development of clinical AD; especially, the time-specific associations were notable: t-tau 8 to 16 years, and Nf-L and GFAP 4 to 8 years prior to clinical AD. 3 key findings →
Design: longitudinal study Participants: 1,327 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Of 386 participants, 199 (52%) were female, and the mean (SD) age was 68 (8) years. 3 key findings →
Design: cohort study Participants: 113 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Blood biomarkers showed significant longitudinal changes corresponding to cognitive decline, clinical AD, and structural MRI characteristics. 5 key findings →
Design: longitudinal study Participants: 1,327 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A higher level of total daily physical activity is associated with a reduced risk of AD. 4 key findings →
Design: cohort study Participants: 71 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Within-person changes in CSF biomarkers were also compared with changes in cortical PiB binding and progression to a CDR higher than 0 at follow-up. 2 key findings →
Design: cohort study Participants: 169 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
However, the clinical presentation, associated factors, frequency in community-based cohorts, genetic characteristics, and cognitive trajectories associated with the quadruple misfolded proteins phenotype are not well understood. 5 key findings →
Design: cohort study Participants: 375 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
At 48 months, group differences between clinical progressors and non-progressors were significant for self (2.13, SE=0.45, P Conclusions and relevance Demonstrating long-term clinical benefit will be critical for the success of recently launched secondary prevention trials. 1 key finding →
Design: longitudinal study Participants: 468 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Medial temporal lobe atrophy seems to be a more important predictor of cognition than small-vessel disease in MCI. 4 key findings →
Design: cohort study Participants: 896 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The Continuum: Dementia for Medical Students curriculum provided an inexpensive and readily implementable means for improving medical knowledge of dementia. 2 key findings →
Design: longitudinal study Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
A cohort of 4 522 160 US veterans (4 243 462 [93.8%] male; median [interquartile range] age, 64.1 [55.7-75.5] years; 3 702 942 [82.0%] white, 667 550 [14.8%] black, and 145 593 [3.2%] other race) was followed up for a median (interquartile range) of 10.0 (6.8-10.2) years. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Greater understanding of the risk factors and mechanisms of incident dementia in stroke survivors is needed for prevention and management. 3 key findings →
Design: longitudinal study Participants: 355 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We observed a complex series of relationships between social-environment variables and cognitive decline and dementia. 3 key findings →
Design: longitudinal study Participants: 2,854 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Intake of coffee alone or in combination with tea was associated with lower risk of poststroke dementia. 3 key findings →
Design: cohort study Participants: 365,682 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This is relevant as the number of old people (a) living alone and (b) suffering from dementia is expected to increase rapidly in the next decades. 2 key findings →
Design: longitudinal study Participants: 201 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 30,980 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,980 records, built mostly from automated pulls of Europe PMC (65.2% of the library) and OpenAlex (16.4%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,042 records (3.4% of the library) are not peer-reviewed — 967 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events